MicroRNA-17/20a impedes migration and invasion via TGF-β/ITGB6 pathway in esophageal squamous cell carcinoma

American Journal of Cancer Research

Volumn 6, Issue 7, 2016, Pages 1549-1562

  Jing, Chao ^a   Ma, Gang ^a   Li, Xukun ^a   Wu, Xiaowei ^a   Huang, Furong ^a   Liu, Kuangyu ^b   Liu, Zhihua ^a  

^a CANCER HOSPITAL   (China)

^b Shenzhen Experimental School   (China)

Author keywords

Esophageal cancer; Invasion; ITGB6; Migration; MiR 17 20a; TGF

Indexed keywords

BETA6 INTEGRIN; MICRORNA; MICRORNA 17; MICRORNA 20A; RECEPTOR REGULATED SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME REPRESSION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LYMPH NODE METASTASIS; MOLECULAR CLONING; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; TUMOR INVASION;

EID: 85006200925     PISSN: None     EISSN: 21566976     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Rustgi AK and El-Serag HB. Esophageal carcinoma. N Engl J Med 2014; 371: 2499-509.
2. Glickman JN. Section II: pathology and pathologic staging of esophageal cancer. Semin Thorac Cardiovasc Surg 2003; 15: 167-79.
3. Pennathur A, Gibson MK, Jobe BA and Luketich JD. Oesophageal carcinoma. Lancet 2013; 381: 400-12.
4. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74.
5. Wan L, Pantel K and Kang Y. Tumor metastasis: moving new biological insights into the clinic. Nat Med 2013; 19: 1450-64.
6. Dykxhoorn DM. MicroRNAs and metastasis: little RNAs go a long way. Cancer Res 2010; 70: 6401-6.
7. Kong KL, Kwong DL, Chan TH, Law SY, Chen L, Li Y, Qin YR and Guan XY. MicroRNA-375 inhibits tumour growth and metastasis in oesophageal squamous cell carcinoma through repressing insulin-like growth factor 1 receptor. Gut 2012; 61: 33-42.
8. Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Watanabe M and Baba H. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 2009; 15: 1915-22.
9. Ma G, Jing C, Li L, Huang F, Ding F, Wang B, Lin D, Luo A and Liu Z. MicroRNA-92b represses invasion-metastasis cascade of esophageal squamous cell carcinoma. Oncotarget 2016; [Epub ahead of print].
10. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008; 133: 217-22.
11. Knuutila S, Bjorkqvist AM, Autio K, Tarkkanen M, Wolf M, Monni O, Szymanska J, Larramendy ML, Tapper J, Pere H, El-Rifai W, Hemmer S, Wasenius VM, Vidgren V and Zhu Y. DNA copy number amplifications in human neoplasms: review of comparative genomic hybridization studies. Am J Pathol 1998; 152: 1107-23.
12. Ota A, Tagawa H, Karnan S, Tsuzuki S, Karpas A, Kira S, Yoshida Y and Seto M. Identification and characterization of a novel gene, C13orf25, as a target for 13q31-q32 amplification in malignant lymphoma. Cancer Res 2004; 64: 3087-95.
13. Li Y, Choi PS, Casey SC, Dill DL and Felsher DW. MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state. Cancer Cell 2014; 26: 262-72.
14. Murphy BL, Obad S, Bihannic L, Ayrault O, Zindy F, Kauppinen S and Roussel MF. Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. Cancer Res 2013; 73: 7068-78.
15. Kim K, Chadalapaka G, Lee SO, Yamada D, Sastre-Garau X, Defossez PA, Park YY, Lee JS and Safe S. Identification of oncogenic micro-RNA-17-92/ZBTB4/specificity protein axis in breast cancer. Oncogene 2012; 31: 1034-44.
16. Chang CC, Yang YJ, Li YJ, Chen ST, Lin BR, Wu TS, Lin SK, Kuo MY and Tan CT. MicroRNA-17/20a functions to inhibit cell migration and can be used a prognostic marker in oral squamous cell carcinoma. Oral Oncol 2013; 49: 923-31.
17. Shimada Y, Imamura M, Wagata T, Yamaguchi N and Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer 1992; 69: 277-84.
18. He H, Li S, Hong Y, Zou H, Chen H, Ding F, Wan Y and Liu Z. Kruppel-like Factor 4 Promotes Esophageal Squamous Cell Carcinoma Differentiation by Up-regulating Keratin 13 Expression. J Biol Chem 2015; 290: 13567-77.
19. Huang G, Nishimoto K, Zhou Z, Hughes D and Kleinerman ES. miR-20a encoded by the miR-17-92 cluster increases the metastatic potential of osteosarcoma cells by regulating Fas expression. Cancer Res 2012; 72: 908-16.
20. Wu Q, Luo G, Yang Z, Zhu F, An Y, Shi Y and Fan D. miR-17-5p promotes proliferation by targeting SOCS6 in gastric cancer cells. FEBS Lett 2014; 588: 2055-62.
21. Massague J, Seoane J and Wotton D. Smad transcription factors. Genes Dev 2005; 19: 2783-810.
22. Yuan Y, Chen H, Ma G, Cao X and Liu Z. Reelin is involved in transforming growth factor-beta1-induced cell migration in esophageal carcinoma cells. PLoS One 2012; 7: e31802.
23. Gupta GP and Massague J. Cancer metastasis: building a framework. Cell 2006; 127: 679-95.
24. Valastyan S and Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell 2011; 147: 275-92.
25. Roussos ET, Condeelis JS and Patsialou A. Chemotaxis in cancer. Nat Rev Cancer 2011; 11: 573-87.
26. Zhang X, Kong Y, Xu X, Xing H, Zhang Y, Han F, Li W, Yang Q, Zeng J, Jia J and Liu Z. F-box protein FBXO31 is down-regulated in gastric cancer and negatively regulated by miR-17 and miR-20a. Oncotarget 2014; 5: 6178-90.
27. Yu Z, Willmarth NE, Zhou J, Katiyar S, Wang M, Liu Y, McCue PA, Quong AA, Lisanti MP and Pestell RG. microRNA 17/20 inhibits cellular invasion and tumor metastasis in breast cancer by heterotypic signaling. Proc Natl Acad Sci U S A 2010; 107: 8231-6.
28. He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ and Hammond SM. A microRNA polycistron as a potential human oncogene. Nature 2005; 435: 828-33.
29. Olive V, Bennett MJ, Walker JC, Ma C, Jiang I, Cordon-Cardo C, Li QJ, Lowe SW, Hannon GJ and He L. miR-19 is a key oncogenic component of mir-17-92. Genes Dev 2009; 23: 2839-49.
30. Bierie B and Moses HL. Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer. Nat Rev Cancer 2006; 6: 506-20.
31. Massague J. TGFbeta signalling in context. Nat Rev Mol Cell Biol 2012; 13: 616-30.
32. Levy L and Hill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 2006; 17: 41-58.
33. Massague J. TGFbeta in Cancer. Cell 2008; 134: 215-30.
34. Kang Y, He W, Tulley S, Gupta GP, Serganova I, Chen CR, Manova-Todorova K, Blasberg R, Gerald WL and Massague J. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005; 102: 13909-14.
35. Mohammad KS, Javelaud D, Fournier PG, Niewolna M, McKenna CR, Peng XH, Duong V, Dunn LK, Mauviel A and Guise TA. TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res 2011; 71: 175-84.
36. Sethi N, Dai X, Winter CG and Kang Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 2011; 19: 192-205.
37. Shi Y and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003; 113: 685-700.
38. Munger JS, Huang X, Kawakatsu H, Griffiths MJ, Dalton SL, Wu J, Pittet JF, Kaminski N, Garat C, Matthay MA, Rifkin DB and Sheppard D. The integrin alpha v beta 6 binds and activates latent TGF beta 1: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 1999; 96: 319-28.